Диссертация (1154359), страница 37
Текст из файла (страница 37)
doi:10.1111/cts.12404.339. Ashburn MA. The evolution of prescription drug monitoring programs /MA Ashburn // Pharmacoepidemiol Drug Saf. - 2016. - doi:10.1002/pds.4036.340.Association of ACE gene D polymorphism with left ventricular hy-pertrophy in patients with diastolic heart failure: a case–control study / E.Bahramali, M. Rajabi, J. Jamshidi[et al.] // BMJ Open. -2016;6(2):e010282.341.Association between angiotensinogen T174M polymorphism and is-chemic stroke: A meta-analysis. Journal of Research in Medical Sciences /Z.
Ou, H. Chen, G. Liu [et al] // The Official Journal of Isfahan Universityof Medical Sciences. – 2015. – Vol.20(6). – P.619-623. doi:10.4103/17351995.165972.342.Association of renin-angiotensin-aldosterone system gene polymor-phisms with left ventricular hypertrophy in hypertensive patients / O. Pavlova; S. Ogurtsova, M. Liventseva [et al.] // Journal of Hypertension. –2015. – Vol.33. – P. 515-516.343.Associations of the –344T>C polymorphism of CYP11B2 gene with24-hour blood pressure profiles in middle-aged women with essential hypertension / M. Sołtysiak, T. Miazgowski, J. Ziemak [et al.] // Arterial Hypertension. – 2015.
- Vol. 19, no 1. – P. 23–28.240344.Associations of ACE polymorphism and diabetic nephropathy sus-ceptibility / H. Ma, C. Yu, R. Wang // International Journal of Clinical andExperimental Medicine. – 2015. – Vol.8(2). – P. 2962-2965.Association between the CYP11B2 gene ˗344T>C polymorphism345.and coronary artery disease: a meta-analysis / Y. Liu, H.L. Liu, W. Han [etal.] // Genetics and Molecular Research. – 2015.
– Vol. 14 (2). – P. 31213128.346.Ayari, I. Role of CYP1A2 polymorphisms in breast cancer risk inwomen/I. Ayari, U. Fedeli [et al.]// Mol Med Rep. – 2013. – Vol. 7 (1):280 – 286.347.Availability of comparative efficacy data at the time of drug approv-al in the United States / N.H. Goldberg, S. Schneeweiss, M.K. Kowal [etal.]. – JAMA. – 2011. – Vol. 305. – P.
1786-1795.348.Bae, J. Effect of CYP2C9*3 allele on the pinetics of naproxen in Ko-rean subjects/ J.Bae, KimJ. [et al.]// Arch Pharm Res. – 2009. – Vol. 32(2): 269- 273.349.Bennett, C.L., et al., Anaphylaxis and hypotension after administra-tion of peginesatide. The New England journal of medicine, 2014.№370(21). - p. 2055-2061.350.Bocquet, F., et al., Biosimilar granulocyte colony-stimulating factoruptakes in the EU-5 markets: a descriptive analysis. Applied health economics and health policy.2014.
-№12(3).- p. 315-341.351.Brusturean-Bota E., Trifa A.P., Coadă C.A. et al.Impact of CYP2C9genetic polymorphisms on valproate dosage, plasma concentrations ofvalproate and clinical response to valproate. // Hum. Veterinary Med. Int. J.Bioflux Soc. – 2013. – Vol. 5. № 3. – P. 94–103.352.Capellier, G. Medication Errors at the Administration Stage in an In-tensive Care Unit / G. Capellier // Intensive Care. Med. – 1999. – Vol.25(4).
– P. 353-359.241353.Cardiovascular risk associated with diastolic blood pressure andisoleted diastolic hypertension. Li Y., Wei F.F., Wang S.1, Cheng Y.B.Current hypertenton reports. 2014.- Vol. 16 (11). P. 1-6. DOI:10.1007/s11906-014-0489.354.Castaneda-Hernandez, G., et al., Biopharmaceuticals for rheumaticdiseases in Latin America, Europe, Russia, and India: Innovators,biosimilars, and intended copies.
Joint, bone, spine:revue du rhumatisme.2014. - №81(6).- p. 471-478.355.Choy, E. and I.A. Jacobs, Biosimilar safety considerations in clinicalpractice. Seminars inoncology. 2014. - №41 Suppl 1. - p. 3-14.356.Claxton, A.J. A systematic review of the associations between doseregimens and medication compliance / A.J. Claxton, J. Cramer, C. Pierce //Clin. Ther. – 2001. – Vol. 23. – P. 1296-310.357.Cohen, N. Pharmacogenomics and Personalized Medicine Nadine/ N.
Cohen // Humana Press. – 2010. - 528 p.358.Compliance and persistence with bisphosphonate dosing regimensamong women with postmenopausal osteoporosis / J.A. Cramer, M.M.Amonkar, A. Hebborn [et al.] // Curr Med Res Opin. – 2005. – Vol. 2. –P. 1453-1460.359.Cost-effectiveness in health and medicine / M.R. Gold, J.E.
Siegel,L.B. Russel [еt al.]. The Journal of Mental Health Policy and Economics J.Mental Health Policy Econ. 1999. - №2. Р. 91–92.360.Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis / W. Van den Hout, Y. Goecoop-Ruiterman, C.Allaart [et al.] // Arthritis & Rheumatism. - 2009. - Vol. 61.
- P. 29.361.Council conclusions on common values and principles in EuropeanUnion health systems // Official Journal of European Union. – 2006. - Vol.49, June. – P. 146-147.242362.Cowell, W. Adherence with bisphosphonate treatment for osteoporo-sis in UK patients / W. Cowell, A. Fulford-Smith, S. Poultney // Bone. –2005.
– Vol. 36(2). – P. 409-419.363.Davis-Ajami, M.L., et al., Epoetin zeta in the management of anemiaassociated with chronickidney disease, differential pharmacology and clinical utility. Biologics :targets & therapy. 2014. - №8.- p. 155-167.364.Derek G. Waller, Antony P.Sampson, Andrew G.Renwick. FourthEdition Medical pharmacology and therapeutics. Saunders Elsevier.
2014.P.730.365.Divino V. Pharmaceutical expenditure on drugs for rare diseases inCanada: a historical (2007-13) and prospective (2014-18) MIDAS salesdata analysis / V Divino, M DeKoven, M Kleinrock [et. Al.]. // Orphanet JRare Dis. – 2016. - №11(1). – P. 68.366.Dmitrenko D.V., Shnayder N.A., Kiselev I.A., Shulmin A.V.,Zhirova N.V., Shapovalova E.A., Kantimirova E.A., Bochanova E.N.,Veselova O.F., Panina Yu.S., Muravieva A.V. Problems of rational therapy for epilepsy during pregnancy. // Open Journal of Obstetrics and Gynecology.- 2014.- Vol. 4, № 9.- P.506-515.367.Drummond, M. Health Technology Assessment in the United King-dom / M.
Drummond, D. Banta // Int J Technol Assessment Health Care. –2009. – Vol. 25(1). – P. 178 – 181.368.Durability and predictors of success of highly active antiretroviraltherapy for ambulatory HIV-infected patients / F.J. Palella, J.S. Chmiel,A.C. Moormana [et al.] // AIDS.
– 2002. – Vol.16. – P. 1617-1626.369.Effect of medication adherence on survival of HIV-infected adultswho start highly active antiretroviral therapy when the CD4 cell count is0.200 to 0.350 x 10 (9) cells/L. / E. Wood, R. Hogg, B. Yip [et al.] //Ann. Intern. Med. – 2003. – Vol.139. – P. 810 – 816.243370.Effect of medication nonadherence on hospitalization and mortalityamong patients with diabetes mellitus / P. Ho, J. Rumsfeld, F. Masoudi [etal.] // Arch.
Intern. Med. – 2006. – Vol. 166. – P. 1836–1841.371.Ehlers, L. Doing minihealth technology assessments in hospitals: anew concept for decision support in health care? / L. Ehlers // International Journal of Technology Assessment in Health Care. – 2016. – Vol.22.
– P. 295–301.372.Eisenberg JM.Clinical economics in clinical trials: the measurementof cost and outcomes in the assessment of clinical services through clinicaltrials / K.A. Schulman, A. Ohishi, J. Park [at al.] // Keio Journal of Medicine. – 1999. - № 1. - P. 1–11.373.Eisenberg, J.K. Globalize the evidence, localize the decision: evi-dence-based medicine and international diversity / J.K. Eisenberg // HealthAffairs. – 2002. – Vol. 21(3). – P.
166-168.374.Egger, T. Identification of adverse drug reaction in geriatric inpa-tients using a computerized drug database/T. Egger, H. Dormann [at al.] //Drugs Aging. – 2003.- Vol. 20 (10). – P.769.375.onEkhart, G. Influence of polymorphisms of drug metabolism enzymesthepharmacokineticsofcyclophosphamide/G.Ekhart,V.Dooderman[at al.] // Pharmacogenetic Genomics. - 2008. - Vol.18. –P.515-523.376.Endothelial Nitric Oxide Synthase 3 (eNOS3) Gene Polymorphismsand Essential Hypertension in Javanese Ethnic Group / A.
Fitranto, A.Saefuddin, M. Alfi // Jurnal Kedokteran Brawijaya. – 2015. – Vol. 28, No 3.- P.182-186.377.Endothelial nitric oxide synthase in the microcirculation / X. Shu,TCS Keller, D. Begandt [et al.] // Cellular and molecular life sciences :CMLS. – 2015. – Vol. 72(23). – P. 4561-4575. doi:10.1007/s00018-0152021-0.244378.Epstein, M.S., E.D. Ehrenpreis, and P.M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
